AlbuminTherapy.com | Information About Albumin Therapy

What is Albumin?

Human albumin is an essential protein found in human plasma accounting for 50%-60% of plasma proteins,1 and is primarily responsible for 75%-80% of plasma's normal colloid oncotic pressure.1

FLEXBUMIN 25% [Albumin (Human)]

FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration.  FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).

Important Risk Information for FLEXBUMIN 25%

FLEXBUMIN 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.

Do not use if turbid.  Do not begin administration more than 4 hours after the container has been entered.

Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for FLEXBUMIN 25%.  Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.

FLEXBUMIN 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.

FLEXBUMIN 25% must be administered intravenously at a rate not to exceed 1 mL/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema. 

When 25% albumin is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.  

Adverse reactions to FLEXBUMIN 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur.

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please see Preparation for Administration for FLEXBUMIN 25% in the Prescribing Information.

Please review the FLEXBUMIN 25% [Albumin (Human)] Prescribing Information for full prescribing details.

BUMINATE 5% [Albumin (Human)], USP, 5% Solution

BUMINATE 5% [Albumin (Human)], USP, 5% Solution is indicated for Hypovolemia, Hypoalbuminemia due to general causes and burns, and use during or prior to cardiopulmonary bypass surgery.

Important Risk Information for BUMINATE 5%

BUMINATE 5% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.

Do not use if turbid.  Do not begin administration more than 4 hours after the container has been entered.

BUMINATE 5% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.

The stoppers used in BUMINATE 5% contain natural rubber latex.  If a patient has a history of cardiac or circulatory disease, BUMINATE 5% should be administered slowly (5 to 10 mL per min) to avoid too rapid a rise in the blood pressure.

Patients should always be monitored in order to guard against the possibility of circulatory overload.

When BUMINATE 5% is used following injuries or surgery, the quick rise in blood pressure which follows administration makes it necessary to monitor the patient to detect and treat severed blood vessels that may not have bled at a lower blood pressure.  

Adverse reactions to BUMINATE 5% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur. Such symptoms usually disappear when the infusion is slowed or stopped for a short period of time.

Please review the BUMINATE 5% [Albumin (Human)] Prescribing Information for full prescribing details.

BUMINATE 25% [Albumin (Human)], USP, 25% Solution

Buminate 25% [Albumin (Human)], USP, 25% Solution is indicated for Hypovolemia, Hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, for use during or prior to cardiopulmonary bypass surgery, and Hemolytic disease of the newborn (HDN).

Important Risk Information for BUMINATE 25%

BUMINATE 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.

Do not use if turbid.  Do not begin administration more than 4 hours after the container has been entered.

Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for BUMINATE 25%.  Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.

BUMINATE 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.

The stoppers used in BUMINATE 25% contain natural rubber latex.

BUMINATE 25% must be administered intravenously at a rate not to exceed 1 mL/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema. 

When BUMINATE 25% is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.  

Adverse reactions to BUMINATE 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur. Such symptoms usually disappear when the infusion is slowed or stopped for a short period of time.

Please see Preparation for Administration for BUMINATE 25% in the Prescribing Information

Please review the BUMINATE 25% [Albumin (Human)] Prescribing Information for full prescribing details.

  1. Gonzalez ER, Kannewurf BS. Clinical review of appropriate uses for albumin. US Pharmacist. 1998;23:HS15-HS26.
  2. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999;39:1160-1168.
  3. FLEXBUMIN 25% [Albumin (Human)], 25% Solution [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; September 2009.
  4. Data on file: Baxter Healthcare Corporation.